Skip to main content
SpringerLink
Log in

Mastocytosis

  • Chapter
  • First Online:
Skin and the Heart

  • 589 Accesses

Abstract

Mastocytosis is a heterogeneous group of pathologies first described in 1872. Mast cell activation syndrome has a variety of features. The WHO criteria for the diagnosis of cutaneous, systemic and smouldering mastocytosis are reviewed, Diagnostic pathways and the latest treatments are explained. Cardiac involvement causing symptoms may occur in the setting of cytokine release especially with anaphyllaxis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Group BMJP. Reports of medical and surgical practice in the hospitals of Great Britain. Br Med J. 1869;2:323–5.

    Google Scholar 

  2. Akin C, Metcalfe DD. Systemic Mastocytosis. Annu Rev Med. 2004;55:419–32.

    CAS  PubMed  Google Scholar 

  3. https://www.orpha.net/consor/cgibin/OC_Exp.php?lng=FR& Expert=98292. Accessed on 18th August 2019.

  4. Damaj G, Hermine O. Systemic mastocytosis in adults: pathophysiology and clinical manifestations. Correspondances en Onco-Hématologie. 2015;X:6.

    Google Scholar 

  5. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    CAS  Google Scholar 

  7. Valent P, Horny HP, Li CY, et al. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) classification of tumours pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2001. p. 291–302.

    Google Scholar 

  8. Horny HP, Akin C, Metcalfe DD, et al. In: Swerdlow SH, Campo PE, Harris NL, Jaffe ES, Pileri SA, Stein H, editors. World Health Organization (WHO) classification of tumours pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008. p. 54–63.

    Google Scholar 

  9. Severino M, Chandesris MO, Barete S, et al. Telangiectasia macularis eruptiva perstans (TMEP): a form of cutaneous mastocytosis with potential systemic involvement. J Am Acad Dermatol. 2016;74:885–91.

    PubMed  Google Scholar 

  10. Bulai Livideanu C, Severino-Freire M, Jendoubi, et al. Image gallery: the vulva: an atypical localization of mastocytosis in adulthood. Br J Dermatol. 2019;181:e33. https://doi.org/10.1111/bjd.17897.

    Article  CAS  PubMed  Google Scholar 

  11. Méni C, Bruneau J, Georgin-Lavialle S, et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015;172:642–51.

    PubMed  Google Scholar 

  12. Pardanani A. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. Am J Hematol. 2016;91:1147–59.

    Google Scholar 

  13. Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. Int Arch Allergy Immunol. 2002;127:137–9.

    PubMed  Google Scholar 

  14. Monnier J, Georgin-Lavialle S, Canioni D, et al. Mast cell sarcoma: new cases and literature review. Oncotarget. 2016;7:66299–309.

    PubMed  PubMed Central  Google Scholar 

  15. Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35–45.

    PubMed  Google Scholar 

  16. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Investig. 2007;37:435–53.

    CAS  Google Scholar 

  17. Kirsten N, Tournier E, Lepage B, et al. Immunohistochemical staining for diagnosis of cutaneous mastocytosis. J Eur Acad Dermatol Venereol. 2016; https://doi.org/10.1111/jdv.13946.

  18. Fradet M, Negretto M, Tournier E, et al. Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study. J Eur Acad Dermatol Venereol. 2019; https://doi.org/10.1111/jdv.15638.

  19. Merante S, Ferretti V, Elena C, et al. The Italian Mastocytosis registry: 6-year experience from a hospital-based registry. Future Oncol. 2018;14:2713–23.

    CAS  PubMed  Google Scholar 

  20. Valent P, Arock M, Bischoff SC, et al. The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr. 2004;116:647–51.

    PubMed  Google Scholar 

  21. Kristensen T, Vestergaard H, Bindslev-Jensen C, Møller MB, Broesby-Olsen S, Mastocytosis Centre, Odense University Hospital (MastOUH). Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol. 2014;89:493–8.

    CAS  PubMed  Google Scholar 

  22. Bulai Livideanu C, Apoil PA, Lepage B, et al. Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. Clin Exp Allergy. 2016;46:133–41.

    CAS  PubMed  Google Scholar 

  23. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727–36.

    CAS  PubMed  Google Scholar 

  24. Ustun C, Arock M, Kluin-Nelemans HC, et al. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica. 2016;101:1133–43.

    CAS  PubMed  Google Scholar 

  25. Pardanani A, Shah S, Mannelli F, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 2018;13:2964–72.

    Google Scholar 

  26. Mannelli F, Gesullo F, Rotunno G, et al. Validation of the Mayo alliance prognostic system for mastocytosis. Blood Cancer J. 2019;18:4–8.

    Google Scholar 

  27. Tefferi A, Shah S, Reichard K, Hanson AC, Pardanani A. Smoldering mastocytosis: survival comparisons with indolent and aggressive mastocytosis. Am J Hematol. 2019;94:E1–2.

    PubMed  Google Scholar 

  28. Siebenhaar F, Förtsch A, Krause K, et al. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy. 2013;68:949–52.

    CAS  PubMed  Google Scholar 

  29. Hermine O, Lortholary O, Leventha P, et al. Case-control cohort study of patients’ perceptions of disability in mastocytosis. PLoS One. 2008;3:e2266. https://doi.org/10.1371/journal.pone.0002266.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jennings S, Slee V, Zack R, et al. Patient perceptions in mast cell disorders. Immunol Allergy. 2018;38:505–25.

    Google Scholar 

  31. Degboé Y, Eischen M, Apoil PA, et al. Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. Osteoporos Int. 2019;30:1235–41.

    PubMed  Google Scholar 

  32. Alvarez-Twose, González-de-Olano D, Sánchez-Muñoz L, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol. 2012;157:275–80.

    CAS  PubMed  Google Scholar 

  33. Bulai Livideanu C, Casassa E, Tournier E et al. Mastocytosis treated with midostaurine: evaluation of response to treatment. Poster No. 376, JDP 2016, Paris.

    Google Scholar 

  34. https://clinicaltrials.gov Accessed on 18 August 2019.

  35. Fatma Jendoubi, Maella Severino-Freire, Carle Paul, Cristina Bulai Livideanu. Omalizumab in the treatment of mast cell disorders: a systematic review of the literature. Poster N°330, JDP 2018, Paris.

    Google Scholar 

  36. Lemal R, Fouquet G, Terriou L, et al. Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS. J Allergy Clin Immunol Pract. 2019;19:30322–8.

    Google Scholar 

  37. González-de-Olano D, Padial-Vilchez MA, Núñez-Acevedo B, et al. Usefulness of omalizumab and sting challenge test in hymenoptera venom allergy and mastocytosis. J Investig Allergol Clin Immunol. 2019; https://doi.org/10.18176/jiaci.0395.

  38. Barete S, Lortholary O, Damaj G, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015;126:1009–16.

    CAS  PubMed  Google Scholar 

  39. Brazzelli V, Grassi S, Merante S, et al. Narrow-band UVB phototherapy and psoralen-ultraviolet a photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. Photodermatol Photoimmunol Photomed. 2016;32:238–46.

    CAS  PubMed  Google Scholar 

  40. Broesby-Olsen S, Farkas DK, Vestergaard H, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study. Am J Hematol. 2016;91:1069–75.

    PubMed  Google Scholar 

  41. Kounis NG, Zavras GM. Histamine-induced coronary artery spasm: the concept of allergic angina. Br J Clin Pract. 1991;45:121–8.

    CAS  PubMed  Google Scholar 

  42. Fassio F, Losappio L, Antolin-Amerigo D, et al. Kounis syndrome: a concise review with focus on management. Eur J Intern Med. 2016;30:7–10.

    CAS  PubMed  Google Scholar 

  43. Paratz DE, Khav N, Burns TA. Systemic mastocytosis, kounis syndrome and coronary intervention: case report and systematic review. Heart Lung Circ. 2017;26:772–8.

    PubMed  Google Scholar 

  44. Ridolo E, Triggiani M, Montagni M, et al. Mastocytosis presenting as cardiac emergency. Intern Emerg Med 2013; 8: 749–52; Rohr SM, Rich MW, Silver KH. Shortness of breath, syncope and cardiacarrest caused by systemic mastocytosis. Ann Emerg Med 2 005; 45: 592–4.

    Google Scholar 

  45. Kolck WU, Haenisch B, Molderings JG. Cardiovascular symptoms in patients with systemic mast cell activation disease. Transl Res. 2016;174:23–32.

    PubMed  Google Scholar 

  46. Indhirajanti S, Van Daele LA, Bos P, et al. Systemic mastocytosis associates with cardiovascular events despite lower plasma lipid levels. Atherosclerosis. 2018;268:152–6.

    CAS  PubMed  Google Scholar 

  47. Magovern GJ, Moraca RJ. Aortic valve replacement in patients with systemic mastocytosis. J Card Surg. 2012;27:189–91.

    PubMed  Google Scholar 

  48. Brockow K, Bonadonna P. Drug allergy in mast cell disease. Curr Opin Allergy Clin Immunol. 2012;12:354–60.

    CAS  PubMed  Google Scholar 

  49. Giraldo-Grueso M, Montes RF, Echeverri D, Umana P, Mitral J. Valve replacement in a patient with systemic mastocytosis. J Cardiothorac Vasc Anesth. 2019;33:877–86.

    Google Scholar 

  50. Dewachter P, Castells CM, Hepner LD, Mouton-Faivre C. Perioperative management of patients with mastocytosis. Anesthesiology. 2014;120:753–9.

    PubMed  Google Scholar 

  51. Dewachter P, Mouton-Faivre C, Cazalaà JB, Carli P, Lortholary O, Hermine O. Mastocytosis and anaesthesia. Ann Fr Anesth Reanim. 2009;28:61–73.

    CAS  PubMed  Google Scholar 

  52. Hermans A, Roeters WM, van Lennep JE, LAP VD, Bot I. Mast cells in cardiovascular disease: from bench to bedside. Int J Mol Sci. 2019;20(14):3395. https://doi.org/10.3390/ijms20143395.

    Article  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Excellence Centre for Mastocytosis (CEREMAST), Toulouse, France

    Cristina Bulai Livideanu, Olivier Lairez & Carle Paul

  2. Department of Dermatology, Toulouse University Hospital, Paul Sabatier University, Toulouse, France

    Cristina Bulai Livideanu & Carle Paul

  3. Department of Cardiology, Toulouse University Hospital, Paul Sabatier University, Toulouse, France

    Olivier Lairez

Authors
  1. Cristina Bulai Livideanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivier Lairez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carle Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristina Bulai Livideanu .

Editor information

Editors and Affiliations

  1. Paediatric Dermatology Department, Colentina Clinical Hospital, “Carol Davila”, University of Medicine and Pharmacy, Bucharest, Romania

    Carmen Salavastru

  2. Professor of Dermatology, University of New South Wales, Sydney, NSW, Australia

    Dedee F. Murrell

  3. Department of Cardiology, Liverpool Hospital, University of New South Wales, Sydney, NSW, Australia

    James Otton

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Livideanu, C.B., Lairez, O., Paul, C. (2021). Mastocytosis. In: Salavastru, C., Murrell, D.F., Otton, J. (eds) Skin and the Heart. Springer, Cham. https://doi.org/10.1007/978-3-030-54779-0_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54779-0_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54778-3

  • Online ISBN: 978-3-030-54779-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation